Virbac SA - Asset Resilience Ratio

Latest as of December 2024: 0.23%

Virbac SA (VIRP) has an Asset Resilience Ratio of 0.23% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Virbac SA (VIRP) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€4.31 Million

≈ $5.04 Million USD Cash + Short-term Investments

Total Assets

€1.90 Billion

≈ $2.22 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Virbac SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VIRP total asset value.

Liquid Assets Composition Over Time

This chart breaks down Virbac SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Virbac SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€4.31 Million	0.23%
Total Liquid Assets	€4.31 Million	0.23%

Asset Resilience Insights

Limited Liquidity: Virbac SA maintains only 0.23% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Virbac SA Industry Peers by Asset Resilience Ratio

Compare Virbac SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
AstraZeneca PLC NASDAQ:AZN	Drug Manufacturers - General	0.10%
Novartis AG MX:NVSN	Drug Manufacturers - General	0.08%
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	0.22%
Novartis AG ADR NYSE:NVS	Drug Manufacturers - General	0.06%
Roche Holding AG SW:ROP	Drug Manufacturers - General	9.82%
Shandong Keyuan Pharmaceutical Co. Ltd. A SHE:301281	Drug Manufacturers - General	6.44%
Firebrick Pharma Ltd AU:FRE	Drug Manufacturers - General	0.29%
Eli Lilly and Company SA:LILY34	Drug Manufacturers - General	6.46%

Annual Asset Resilience Ratio for Virbac SA (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Virbac SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.23%	€4.31 Million ≈ $5.04 Million	€1.85 Billion ≈ $2.16 Billion	+0.06pp
2023-12-31	0.17%	€2.50 Million ≈ $2.92 Million	€1.46 Billion ≈ $1.70 Billion	-0.01pp
2022-12-31	0.18%	€2.49 Million ≈ $2.91 Million	€1.36 Billion ≈ $1.59 Billion	+0.04pp
2021-12-31	0.15%	€1.78 Million ≈ $2.08 Million	€1.22 Billion ≈ $1.43 Billion	-0.52pp
2020-12-31	0.67%	€7.39 Million ≈ $8.64 Million	€1.11 Billion ≈ $1.30 Billion	+0.64pp
2019-12-31	0.03%	€342.00K ≈ $399.83K	€1.32 Billion ≈ $1.55 Billion	-0.03pp
2018-12-31	0.06%	€739.00K ≈ $863.97K	€1.27 Billion ≈ $1.49 Billion	-0.05pp
2017-12-31	0.11%	€1.34 Million ≈ $1.57 Million	€1.28 Billion ≈ $1.49 Billion	+0.02pp
2013-12-31	0.08%	€735.00K ≈ $859.29K	€896.23 Million ≈ $1.05 Billion	-0.11pp
2011-12-31	0.19%	€1.14 Million ≈ $1.34 Million	€588.63 Million ≈ $688.18 Million	--

pp = percentage points

About Virbac SA

PA:VIRP France Drug Manufacturers - General

Market Cap

$3.04 Billion

€2.60 Billion EUR

Market Cap Rank

#4939 Global

#83 in France

Share Price

€310.50

Change (1 day)

-1.27%

52-Week Range

€302.00 - €384.00

All Time High

€437.64